未登录

J

Jie Xu

Peking University

H指数:21

被引数:2,210

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study

阿帕替尼联合异环磷酰胺和依托泊苷与异环磷酰胺和依托泊苷在晚期骨肉瘤患者中的比较（OAIE/PKUPH-sarcoma 11）：一项随机II期研究

Nature Communications

IF15.7

2025-11-250

OAAI

Genomic profiling and pathological assessment of malignant peripheral nerve sheath tumors

恶性周围神经鞘瘤的基因组分析与病理评估

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

IF2.8

2025-05-140

OA

Optical genome mapping reveals diverse mechanisms of cyclin activation in mantle cell lymphomas lacking IGH::CCND1

光学基因组图谱揭示了在缺乏IGH::CCND1的套细胞淋巴瘤中细胞周期蛋白活化的多种机制

HUMAN PATHOLOGY

IF2.6

2025-05-010

PRE

Integrative analysis of Ewing's sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy

CELL COMMUNICATION AND SIGNALING

IF8.9

2025-01-131

OAAI

The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma

IF3.4

2024-02-031

OAAI

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)

IF3.4

2023-09-156

OAAI

Intravoxel incoherent motion and dynamic contrast-enhanced magnetic resonance imaging for neoadjuvant chemotherapy response evaluation in patients with osteosarcoma

EUROPEAN JOURNAL OF RADIOLOGY

IF3.3

2023-05-017

PRE

Distinct genomic features between osteosarcomas firstly metastasing to bone and to lung

IF3.6

2023-05-011

OAAI

Improvement of radiotherapy with an ozone-carried liposome nano- system for synergizing cancer immune checkpoint blockade

IF10.9

2022-12-0110

PRE

Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy

全身治疗完全缓解后，具有广泛肺/胸膜转移的尤文肉瘤患者的长期预后和复发模式

IF3.4

2022-05-061

OAAI

Novel anti-PD-L1 antibody TQB2450 (T) in combination with anlotinib (A) in patients with advanced soft tissue sarcoma (STS), the results from the expanded sample size and updated data

ANNALS OF ONCOLOGY

IF65.4

2021-12-010

OA

Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience

FRONTIERS IN ONCOLOGY

IF3.3

2021-07-226

OAAI

Short-term but not long-term high fat diet feeding protects against pressure overload-induced heart failure through activation of mitophagy

IF5.1

2021-05-0120

PREAI

Improving Bioavailability of Hydrophobic Prodrugs through Supramolecular Nanocarriers Based on Recombinant Proteins for Osteosarcoma Treatment

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

IF16.9

2021-04-0847

PREAI

The Clinical Implications of Tumor Mutational Burden in Osteosarcoma

骨肉瘤中肿瘤突变负荷的临床意义

FRONTIERS IN ONCOLOGY

IF3.3

2021-04-0714

OAAI

Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China

IF3.4

2021-03-314

OAAI

Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs

IF10.1

2021-03-01311

PREAI

Apatinib for treatment of inoperable metastatic or locally advanced chondrosarcoma: What we can learn about the biological behavior of chondrosarcoma from a multicenter study

ANNALS OF ONCOLOGY

IF65.4

2020-09-011

OAAI

Dynamic changes in quality of life and Q-TWiST analysis for Ewing sarcoma patients following anlotinib and irinotecan: A combination of phase Ib and II trial

ANNALS OF ONCOLOGY

IF65.4

2020-09-010

OAAI

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?

IF3.4

2018-10-1617

OAAI